Aaron Tachibana Sells 1,201 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 1,201 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $11.50, for a total value of $13,811.50. Following the sale, the chief financial officer owned 164,458 shares of the company’s stock, valued at approximately $1,891,267. This represents a 0.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Aaron Tachibana also recently made the following trade(s):

• On Tuesday, November 25th, Aaron Tachibana sold 103,668 shares of Personalis stock. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04.

Personalis Price Performance

Shares of NASDAQ PSNL opened at $10.17 on Friday. The firm has a market cap of $903.10 million, a price-to-earnings ratio of -11.56 and a beta of 1.96. The stock’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $7.47. Personalis, Inc. has a one year low of $2.83 and a one year high of $11.50.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. On average, equities analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

PSNL has been the topic of a number of analyst reports. Needham & Company LLC increased their price target on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. BTIG Research reaffirmed a “buy” rating and issued a $12.00 price target on shares of Personalis in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Thursday. Finally, Guggenheim raised their target price on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PSNL. Kennedy Capital Management LLC lifted its holdings in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after acquiring an additional 1,281,695 shares during the last quarter. Aberdeen Group plc lifted its stake in Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the last quarter. Geode Capital Management LLC lifted its stake in Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after purchasing an additional 851,422 shares during the last quarter. ARK Investment Management LLC boosted its position in Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares in the last quarter. Finally, Blue Water Life Science Advisors LP grew its stake in shares of Personalis by 42.6% during the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after buying an additional 500,900 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.